title: [Evaluation of the results of combined treatment of patients with testicular seminoma in the II stage of clinical advancement].
abstract: An attempt to introduce combined therapy for patients with testicular seminoma in the II degree of clinical advancement was undertaken at the Centre of Oncology. Combined therapy consisted of 3 courses of PVB in the following daily doses: DDP 100 mg/m2 i.v. on the first day; VLB 10 mg i.v. on the first and second day; bleomycin 30 mg i.v. on the second, ninth and sixteenth day every 21 days, and 60Co on lymphatic glands area in which metastases were diagnosed prior to chemotherapy. Twenty three patients were treated that way between January 1985 and June 1989. Mean follow-up period after the treatment was 14 months. One patient died for the tumor, metastases to the lungs were diagnosed in one patient 9 months after completion of the treatment which ameliorated after "second" chemotherapy, and 22 patients (96%) are still free from the symptoms of active disease.
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003037:Cobalt Radioisotopes / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004407:Dysgerminoma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D015182:Lymphatic Irradiation; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D012074:Remission Induction; D012187:Retroperitoneal Space / Q000528:radiation effects; D013736:Testicular Neoplasms / Q000473:pathology / Q000628:therapy*; D013737:Testis / Q000187:drug effects* / Q000473:pathology / Q000528:radiation effects; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D003037:Cobalt Radioisotopes; D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin
vernacular_title: Ocena wyników skojarzonego leczenia chorych na nasieniaki jadra w II stopniu zaawansowania klinicznego.